tbuckley/cabot-search huggingface dataset:
Abstract B24: Regulation of mutant p53 stability by the mevalonate pathway-Hsp40-CHIP axis
Authors: Alejandro Parrales, Atul Ranjan, Swathi V. Iyer, Scott Weir, Anuradha Roy, Tomoo Iwakuma
Journal: Clinical Cancer Research (2017)

Abstract Missense mutations in the p53 gene result in accumulation of dysfunctional p53 proteins in tumors with oncogenic gain-of-function activities, such as metastasis and chemotherapy resistance. Increasing evidence indicates that stabilization of mutant p53 (mutp53) in tumors is crucial for its oncogenic activities, while its knockdown reduces malignant progression. Thus, malignant properties of cancer cells are dependent on the presence of mutp53, providing a rationale to identify compounds that deplete mutp53 with minimal effects on wild-type p53 (wtp53). Toward this goal, we performed luciferase assay-based high-throughput screening of ~9,000 chemical compounds using cells expressing a chimeric fusion protein of p53R175H and a luciferase reporter. This screening led us to identify statins, a class of cholesterol-lowering drugs, as degradation inducers of conformational p53 mutants. Interestingly, statins showed minimal effects on wtp53 and DNA contact mutants. Moreover, CHIP ubiquitin ligase, but not MDM2, mediated statin-induced nuclear export, ubiquitination, and degradation of mutp53. Surprisingly, degradation of mutp53 by statins was independent of protein prenylation/lipidation or cholesterol synthesis, and specific reduction of mevalonte-5-phosphate (MVP) triggered mutp53 degradation. We also demonstrated that downregulation of a molecular chaperone Hsp40/DNAJA1 mirrored statin's effects on mutp53, while its overexpression nullified them. Moreover, statin-induced reduction of MVP inhibited the DNAJA1-mutp53 interaction. Biologically, statins preferentially suppressed malignant properties of mutp53-expressing cancer cells in vitro and in vivo. Our study proposes a novel role of DNAJA1 in inhibiting CHIP-mediated degradation of mutp53 induced by statins and highlights the significance of p53 status in impacting the efficacy of statins in cancer therapy and of DNAJA1 as a viable target for inducing mutp53 degradation. Citation Format: Alejandro Parrales, Atul Ranjan, Swathi V. Iyer, Scott Weir, Anuradha Roy, Tomoo Iwakuma. Regulation of mutant p53 stability by the mevalonate pathway-Hsp40-CHIP axis. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B24.
P1.02-066 Genomic Profiling in the Differential Diagnostics of Pulmonary Tumors: A Case Series
Authors: Kajsa Ericson Lindquist, Anna Johansson, Per Levéen, Göran Elmberger, Göran Jönsson, Johan Staaf, Hans Brunnström
Journal: Journal of Thoracic Oncology (2017)
MA06.03 Recurrence Dynamics after Trimodality Therapy (Neoadjuvant Chemoradiotherapy and Surgery) in Stage IIIa(N2) Lung Cancer
Authors: Jung Hee Lee, Hong Kwan Kim, Byung Jo Park, Yong Soo Choi, Jong Ho Cho, Jae Ill Zo, Young Mog Shim, Sumin Shin, Hong Ryull Pyo, Yong Chan Ahn, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jhingook Kim
Journal: Journal of Thoracic Oncology (2017)
P1.08-057 Outcomes between Single Port, Two Port and Three Port VATS Pulmonary Resection
Authors: Juwei Mu, Shugeng Gao, Qi Xue, Yousheng Mao, Dali Wang, Jun Zhao, Yushun Gao, Jinfeng Huang, Jie He
Journal: Journal of Thoracic Oncology (2017)
P228 Is the brompton bpat a useful tool to assess breathing pattern disorder in asthma?
Authors: SJ Todd, R Livingston, L Grillo, A Menzies-Gow, J Hull
Journal: Thorax (2016)

<h3>Introduction</h3> Breathing pattern disorder (BPD) is a prevalent cause for persistent dyspnoea in patients with asthma. The diagnosis of BPD is difficult and currently relies exclusively on subjective assessment with no reliable diagnostic tools currently validated to support a clinical assessment. <h3>Aim</h3> To determine if the Brompton Breathing Pattern Assessment Tool (BPAT) has value in the assessment of BPD. <h3>Method</h3> We audited an objective scoring tool, the BPAT, in patients with asthma and/or unexplained dyspnoea completing a systematic multi-disciplinary assessment. The BPAT (score 0 to 14) evaluates aspects of breathing (including; rate, flow, pattern, rhythm and air hunger). This was compared against BPD diagnosis made by current MDT practise. BPAT measures were also compared with indices of dyspnoea/disease control; e.g. walking test, Dyspnoea 12 (D12), Nijmegen and Asthma Quality of Life Questionnaire (AQLQ). <h3>Results</h3> 75 patients; n = 54 females, were divided into 3 groups by diagnosis (asthma, asthma+BPD and BPD alone). BPAT was statistically significantly different between all groups (Table). It also correlated statistically significantly with both the D12 score (r = 0.586, N = 23, p = 0.003) and Nijmegen score (r = 0.418, N = 24, p = 0.042) in the BPD group. There was no relationship between BPAT and FEV<sub>1</sub>% predicted or 6MWT distance. <h3>Conclusion</h3> The BPAT score was higher in those patients diagnosed with BPD both with and without asthma. The BPAT score also correlates with both the D12 and Nijmegen score in patients diagnosed with BPD. This suggests it detects and characterises common aspects of BPD. Further work is now needed to validate the BPAT and determine its responsiveness to intervention.
Activation of C/EBPa Myeloid-Specific Transcription Factor By NAMPT/SIRT1-Triggered Deacetylation
Authors: Bardia Samareh, Masoud Nasri, Inna Zimmer, Olga Klimenkova, Leonie Keller, Lothar Kanz, Karl Welte, Julia Skokowa
Journal: Blood (2015)
Association Between CYP3A4 Polymorphisms, Trough Imatinib Plasma Concentration and Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia (CML-CP)
Authors: Vikram Gota, Anupam Sharma, Amey Paradkar, Anand Patil, Navin Khattry, Hari Menon, Anuradha Choughule, Pratibha Amare, Shripad Banavali, Brijesh Arora
Journal: Blood (2012)
OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study)
Authors: Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, Hervé Léna, Benjamin Besse, Michèle Beau-Faller, Jean Mosser, Eric Pichon, Jean-Philippe Merlio, L'Houcine Ouafik, François Guichard, Bénédicte Mastroianni, Lionel Moreau, Annie Wdowik, Jean-Christophe Sabourin, Antoinette Lemoine, Pascale Missy, Alexandra Langlais, Denis Moro-Sibilot, Julien Mazieres
Journal: Journal of Thoracic Oncology (2017)
Monitoring of Incipient Haematological Relapse by CD34+ Donor Chimerism Determination in Patients with Acute Myelogenous Leukaemia and Myelodysplastic Syndrome after Allogeneic Hematopoietic Cell Transplantation (HCT) Following Low Dose TBI-Based Conditioning Regimens.
Authors: Dietger W. Niederwieser, Claudia Nehring, Rainer Krahl, Cornelia Becker, Sabine Leiblein, Jeanett Edelmann, Wolf-Dieter Kortmann, Wolfram Poenisch, Thoralf Lange, Haifa K. Al-Ali
Journal: Blood (2007)
Rescue technique using a diathermic dilator for an unremovable stent in malignant perihilar biliary obstruction
Authors: Ryo Sugiura, Hiroshi Kawakami, Nobuyuki Ehira, Ichiro Iwanaga, Minoru Uebayashi, Masaki Kuwatani, Naoya Sakamoto
Journal: Endoscopy (2017)

Endoscopic biliary stenting is a useful and safe technique for malignant biliary obstructions. A plastic stent is frequently used because of its low cost and ease of deployment. However, it is occasionally difficult to remove a plastic stent because of severe stricture. We describe a rescue technique for immovable plastic stents, using a diathermic dilator in a case of perihilar biliary obstruction.
HLA-DRB4 Mismatch Is Associated with Worse Outcomes in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Authors: Marie Y. Detrait, Ibrahim Yakoub-Agha, Valerie Dubois, Françoise Dufossé, Myriam Labalette, Mohamad Sobh, Stéphane Morisset, Nathalie Tedone, Sylvie Rey, Elodie Morais, Mauricette Michallet
Journal: Blood (2012)
P2.03b-039 Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression
Authors: Luis Raez, Kathleen Danenberg, Brian Hunis, Aurelio Castrellon, Yolanda Jaimes, Michel Velez, Joshua Usher, Cheryl Habaue, Peter Danenberg
Journal: Journal of Thoracic Oncology (2017)
The single-nucleotide polymorphism T&gt;C rs4353229 in CASP7 gene and mir-224 as new biomarkers of oxaliplatin-induced neurotoxicity in advanced colorectal cancer.
Authors: José Carlos Villa Guzman, Ruth Zarate, Valentina Boni, A. Gomez, Juan R. De la Haba, Eva Bandres, Jesus Garcia-Foncillas, Enrique Aranda
Journal: Journal of Clinical Oncology (2012)

513 Background: Oxaliplatin represents a central component of colorectal (CCR) cancer treatment. It is known that the ways in which oxaliplatin is neurotoxic include not only DNA damage, but also the modulation of specific molecules, such as caspases 3 and 7, involved in regulating the cellular equilibrium between apoptotic death and the cell cycle. MiRNAs are non-coding RNAs that can block mRNA traslation. Recent evidences indicate that variations in miRNA binding sites may contribute to the susceptibility to CCR. However, the effect of these SNPs on miRNA-target interaction remains to be determined. The SNP T&gt;C rs4353229 in CASP7 gene is binding site of miR-224. We hypothesize that miR-224 and the SNP T&gt;C rs4353229 could be new predictive biomarkers of oxaliplatin-induced neurotoxicity in advanced colorectal cancer. Methods: We examined the SNP T&gt;C rs4353229 in CASP7 gene in 62 patients with advanced CCR. All patients had received first line of chemotherapy based in fluoropirimidines plus oxaliplatin. The Oxaliplatin-Specific Neurotoxicity Scale was utilized to assess oxaliplatin-related symptoms. Time to progresion (TTP) and objetive response rate (ORR) were calculated. Genomic DNA was extracted from peripheral blood and genotyped by allelic discrimination. We explored the possible correlation of rs4353229 with neurotoxicity, DCR and TTP using and Chi-cuadrado test and Kaplan-Meier model (log rank) respectively. Results: SNP distribution was 3,2% (ancestral homozygous CC), 46,7% (variant homocygous TT) and 43,7% (heterocygous CT). Median TTP was 10 months (IC 95% : 7,4-12,5); regarding CASP7 polymorphism, there were not differences (p=0,41; log rank). ORR was 64,5% and there are not differences between CC, CT and TT patients (p=0,50). Fifteen patients experienced neurotoxicity grade III/IV (24,19%) and it was correlated significantly with ancestral homoygous CC patients (p=0,003). Conclusions: The SNP T&gt;C rs4353229 in CASP7 gene and miR-224 may be new candidates predictor of oxaliplatin-induced neurotoxicity. Further characterization of CASP7 SNPs and miR-224 may open new avenues for the study of cancer and therapeutic interventions.
Cancellation of c-MYC Silencing in Human Induced Pluripotent Stem Cells Contributes to the Efficient in Vitro Production of Platelets with the Ability of Hemostasis In Vivo.
Authors: Naoya Takayama, Sou Nakamura, Satoshi Nishimura, Ryoko Ohnishi, Kazutoshi Takahashi, Shinya Yamanaka, Koji Eto, Hiromitsu Nakauchi
Journal: Blood (2009)
OA08.03 MET Copy Number Gain Associates with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR Mutant Lung Cancer
Authors: Seiji Yano, Shigeki Nanjo, Sachiko Arai, Shinji Takeuchi, Tadaaki Yamada, Yasunori Okada, Akito Hata, Nobuyuki Katakami
Journal: Journal of Thoracic Oncology (2017)
P3.01-014 Differential Gene Expression of Lung Adenocarcinoma Histology Subtypes According to the IASLC/ATS/ERS Classification
Authors: Oscar Arrieta, Camilo Molina Romero, Claudia Rangel Escareño, Alette Ortega Gómez, Alejandro Aviles Salas, Federico Avila Moreno, Gabriela Mercado-Célis, Andrés Cardona
Journal: Journal of Thoracic Oncology (2017)
OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
Authors: Josine Quispel-Janssen, Giulia Zago, Robert Schouten, Wieneke Buikhuisen, Kim Monkhorst, Eric Thunissen, Paul Baas
Journal: Journal of Thoracic Oncology (2017)
P1.02-079 DNA Ploidy, CPA4 and Rel B Expression in Non-Small Cell Lung Cancer: Correlation with Clinicopathologic Parameter
Authors: Kyriakos Hainis, Eleftheria Haini, Angelos Tsipis, Maria Gonidi, Pauline Athanassiadou, Anna Maria Athanassiadou
Journal: Journal of Thoracic Oncology (2017)
Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis
Authors: Nao Nishida-Aoki, Naoomi Tominaga, Fumitaka Takeshita, Hikaru Sonoda, Yusuke Yoshioka, Takahiro Ochiya
Journal: Molecular Therapy (2017)

Metastasis is the main cause of cancer mortality for many types of cancer; however, difficulties remain in effectively preventing metastasis. It has been recently and widely reported that cancer-derived extracellular vesicles (EVs) contribute to cancer metastasis. Thus, therapeutic strategies targeting cancer-derived EVs hold great promise because of the possibility of EVs driving the cancer microenvironment toward metastasis. Here, we provide a novel strategy for therapeutic antibody treatment to target cancer-derived EVs and inhibit the metastasis of breast cancer in a mouse model, establishing a rationale for further clinical investigation. Treatment with human-specific anti-CD9 or anti-CD63 antibodies significantly decreased metastasis to the lungs, lymph nodes, and thoracic cavity, although no obvious effects on primary xenograft tumor growths were observed. In in vitro and in vivo experiments, the EVs incubated with the targeted antibodies were preferentially internalized by macrophages, suggesting that antibody-tagged cancer-derived EVs would be eliminated by macrophages. Our results suggested that therapeutic antibody administration effectively suppresses EV-triggered metastasis in cancer and that the removal of EVs could be a novel strategy for cancer therapy.
P3.02c-069 Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Authors: Stephen Bagley, Shawn Kothari, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey Evans, John Kosteva, Christine Ciunci, Jeffrey Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby-Sandy, Faith Mutale, Gloria Dilullo, Roger Cohen, Anil Vachani, Corey Langer
Journal: Journal of Thoracic Oncology (2017)
Day 45 Lymphocyte Recovery Is Independently Associated with Transplant-Related Mortality after Adult Myeloablative Double-Unit Cord Blood Transplantation (dCBT)
Authors: Duncan Purtill, Doris M. Ponce, Sean M. Devlin, Marissa N Lubin, Parastoo B Dahi, Sergio A Giralt, Miguel-Angel Perales, Richard J. O'Reilly, Marcel R.M. van den Brink, James W. Young, Andromachi Scaradavou, Cladd Stevens, Juliet N. Barker
Journal: Blood (2014)
P2.02-034 Both Induction and Adjuvant Treatment Improve Outcomes of Surgically-Resected IIIA(N2) NSCLC When Compared to Definitive Chemoradiotherapy
Authors: Patrick Villeneuve, Daniel Corsi, Joshua Hefler, Caitlin Anstee, Sebastien Gilbert, Donna Maziak, Andrew Seely, Farid Shamji, Tim Ramsay, Sudhir Sundaresan
Journal: Journal of Thoracic Oncology (2017)
Abstract A44: A landscape of pharmacogenomic interactions in cancer
Authors: Francesco Iorio, Theo Knijnenburg, Daniel vis, Graham Bignell, Michael Menden, Lodewyk Wessels, Julio Saez-Rodriguez, Ultan McDermott, Mathew Garnett
Journal: Clinical Cancer Research (2017)

Abstract Systematic studies of cancer genomes are providing unprecedented insights into the molecular nature of human cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here we report how cancer-driving alterations identified in 11,289 tumors from 29 tissues (integrating mutations, copy-number alterations, methylation and gene expression) correlate with response to 265 compounds profiled in 1,001 human cancer cell-lines. We find that cell-lines faithfully recapitulate oncogenic aberrations identified in tumors, and that many of these associate with drug sensitivity or resistance. Logic-based modeling uncovers combinations of aberrations that specifically sensitize to drugs, while machine-learning demonstrates the redundancy of different molecular data types in predicting drug response. Our comprehensive analysis and associated datasets are rich resources to identify novel therapeutic options for selected cancer sub-populations. Citation Format: Francesco Iorio, Theo Knijnenburg, Daniel vis, Graham Bignell, Michael Menden, Lodewyk Wessels, Julio Saez-Rodriguez, Ultan McDermott, Mathew Garnett. A landscape of pharmacogenomic interactions in cancer. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A44.
PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).
Authors: Geraldine Gebhart, Laetitia E. Lamberts, Camilo Garcia, Lieveke Ameye, Sigrid Stroobants, Manon Huizing, Philippe G. Aftimos, Jolien Tol, Wim J.G. Oyen, Zena Wimana, G.A.M.S. van Dongen, Otto S. Hoekstra, Carolien P. Schroder, Julie Gaye, Catharina Wilhelmina Menke, Thomas Guiot, Adrienne H. Brouwers, Ahmad Awada, Elisabeth G. E. de Vries, Patrick Flamen
Journal: Journal of Clinical Oncology (2014)

11001 Background: So far, no biomarker beyond HER2 status by immunohistochemistry (IHC) or in situ hybridization (ISH), has been validated to predict treatment efficacy of T-DM1, a novel antibody-drug conjugate targeting HER2. Zephir is a multicenter study designed to explore the role of molecular imaging in identifying patients with HER2 positive mBC (pre-treated with any number of treatment lines) unlikely to benefit from T-DM1. Here we report the results of a planned interim analysis. Methods: Fifty-two (of 105 foreseen) patients with HER2 positive BC (IHC 3+ or FISH ≥ 2.2) underwent one pre-treatment HER2 PET/CT (4 days after administration of 37 MBq zirconium-89-trastuzumab), and 3 serial FDG PET/CT: at baseline, before the 2nd cycle (early FDG), and after 3 cycles of T-DM1 (late FDG). Central standardization and validation of acquisition parameters were performed. A patient-based imaging analysis was conducted by two independent reviewers and discordances were revised by a third investigator. HER2 PET/CT was considered negative if all or the major part of the metastatic tumor load showed no or minimal tracer uptake (≤ local background). FDG PET/CT response was classified as negative if all or the major part of metastatic tumor load showed no significant metabolic response (cut-offs set at 15% for early and 30% for late FDG PET/CT). Negative and positive predictive values (NPV and PPV) of HER2 PET/CT, early FDG response, and their combination for the prediction of late FDG PET/CT response were assessed. Results: HER2 PET/CT was scored negative in 17 (32%) patients, reflecting substantial imaging heterogeneity between patients considered as HER2 positive. PPV and NPV of HER2 PET/CT, early FDG PET/CT and their combination are summarized in the Table. Conclusions: Pre-treatment HER2 imaging and early FDG response assessment after 1 cycle seem very promising in identifying patients unlikely to show a metabolic response after 3 cycles of T-DM1. Clinical trial information: NCT01565200. Classification N patients Late FDG PET PPV NPV R NR HER2 PET + 34 26 8 76% - 17 4 13 76% Early FDG PET R 26 26 0 100% NR 26 5 21 81% HER2 PET / Early FDG PET + / R 23 23 0 100% - / NR 14 1 13 92% Abbreviations: R, metabolic response; NR, metabolic nonresponse.
P2.03b-080 A Comprehensive Test of Cancer Treatment-Related Genes for the Clinical Samples of Non-Small Cell Lung Cancer (NSCLC)
Authors: Yoshiaki Inoue, Ato Sugiyama, Kohei Aoki, Hiroki Fukuda, Masatoshi Gika, Yotaro Izumi, Kunihiko Kobayashi, Mitsuo Nakayama, Koichi Hagiwara
Journal: Journal of Thoracic Oncology (2017)
Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies
Authors: Adam M. Petrich, Leo I. Gordon, Jeffrey R. Infante, Sumit Madan, Francis J. Giles, Halla S. Nimeiri, Jason B. Kaplan, Kate Stumpo, Bin Zhang, Stephanie Faucette, Yaping Shou, Kent C. Shih
Journal: Blood (2015)
Characterization of Gene Expression Profiles of Plasma Cells in Patients with Multiple Myeloma.
Authors: Manoela M. Ortega, Anderson F. Cunha, Dulcineia M. Alberquerque, Adriana S.S Duarte, Carmino De Souza, Irene Lorand-Metze, Fernando F. Costa, Carmen S.P. Lima
Journal: Blood (2006)
P1.02-005 Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR)
Authors: Elisa Chiadini, Angelo Delmonte, Laura Capelli, Nicoletta De Luigi, Alessandro Gamboni, Claudia Casanova, Claudio Dazzi, Maximilian Papi, Sara Bravaccini, Maria Maddalena Tumedei, Alessandra Dubini, Maurizio Puccetti, Lucio Crinò, Paola Ulivi
Journal: Journal of Thoracic Oncology (2017)
Effect of Iron Levels on Women After Premature or Early-Onset Menopause—Reply
Authors: Taulant Muka, Rajiv Chowdhury, Oscar H. Franco
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Clinical Meanings of Quantitative PCR of Patient-Specific Immunoglobulin VDJ Regions Using Various Materials of Myeloma Patients
Authors: Hiroshi Sata, Hirohiko Shibayama, Ikuhiro Maeda, Yoko Habuchi, Eiji Nakatani, Kentaro Fukushima, Jiro Fujita, Sachiko Ezoe, Seiji Tadokoro, Tetsuo Maeda, Masao Mizuki, Satoru Kosugi, Masashi Nakagawa, Shuji Ueda, Masato Iida, Yukihiro Tokumine, Hideki Mitsui, Yasuhiko Azenishi, Kenji Oritani, Yuzuru Kanakura
Journal: Blood (2014)
An IELSG International Survey of Primary Effusion Lymphoma (PEL).
Authors: Annarita Conconi, Michele Spina, Valeria Ascoli, Armando Lopez-Guillermo, Sergio Cortelazzo, Re Alessandro, Ryo Ichinohasama, Tetsutaro Sata, Mario Luppi, Daniele Vallisa, Cesare Bergonzi, Mariano Provencio, Davide Rossi, Alexandra Levine, Martine Raphael, Abraham Klepfish, Annunziata Gloghini, Sophie Prevot, Gianluca Gaidano, Antonino Carbone
Journal: Blood (2004)
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
Authors: Bruce Strober, Alice B. Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G. Lebwohl
Journal: Journal of the American Academy of Dermatology (2017)
DOES EARLY PERIOPERATIVE GOAL DIRECTED THERAPY USING FUNCTIONAL AND VOLUMETRIC HEMODYNAMIC PARAMETERS IMPROVE THERAPY IN CARDIAC SURGERY? A PROSPECTIVE, RANDOMIZED CONTROLLED TRLAL
Authors: M. S. Goepfert, H. P. Richter, J. C. Kabitz, A. von Sandersleben, J. Gruetzmacher, E. Rafflenbeul, K. Roeher, C. Zu Eulenburg, H. Reichenspurner, A. E. Goetz, D. A. Reuter
Journal: Intensive Care Medicine (2011)